Low-Grade Serous Ovarian Cancer is rare and subtle, but awareness matters. Know the signs.

Read more: disabilityhorizons.com/2025/09/lgso...
#LGSOC #CancerAwareness #WomensHealth

Avutometinib and Defactinib in Recurrent LGSOC: Results Explore the phase II trial results of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

New Paper Alert: Avutometinib and Defactinib Combination for Recurrent LGSOC – Phase II Trial Results

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LGSOC #Avutometinib #Defactinib #OvarianCancer

The FDA approval on Thurs for Verastem was under the accelerated approval program (1st cancer drug AA was in 1995) & based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients w/ KRAS mutant recurrent low-grade serous ovarian cancer. #biosky #ovariancancer #LGSOC

Needham, MA-based Verastem Oncology
received its 1st FDA approval on Thurs—for 1st-ever treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer. Combo of avutometinib & defactinib targets RAS/MAPK pathway fiercepharma.com/pharma/veras.... #ovariancancer #LGSOC. #biosky